Jessica Hedvat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jessica Hedvat has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- David M. Salerno
Department of Pharmacy NewYork‐Presbyterian Hospital New York New York USA
13 shared publications - Nicholas W. Lange
NewYork Presbyterian Hosp, Dept Pharm, New York, NY USA
12 shared publications - Douglas L. Jennings
Thomas J. Long School of Pharmacy University of the Pacific Sacramento California USA
5 shared publications - Jennifer H. Lee
Department of Pharmacy NewYork‐Presbyterian Hospital New York NY USA
5 shared publications - Marcus R. Pereira
Division of Infectious Diseases Department of Medicine Columbia University Irving Medical Center New York City New York USA
5 shared publications - Danielle Kovac
Department of Pharmacy New York Presbyterian Hospital New York New York USA
4 shared publications
Latest Publications
- 8 August 2024
- Published by Wiley in Clinical Transplantation
- Vol. 38 (8) , e15420
Contemporary Immunosuppression Management and 1‐Year Outcomes in Dual Organ Heart Transplantation
Background: There have been limited reports on immunosuppression strategies and outcomes in dual organ heart transplant populations, primarily from before the 2018 United Network for Organ Sharing (UNOS) heart allocation policy change. Recent data suggested that outcomes with heart–lung and heart–liver transplants remained comparable in the new allocation era, yet heart–kidney recipients have worse 1‐year survival.Methods: This single‐center retrospective study evaluated adult heart–kidney, heart–liver, and heart–lung transplant recipients from September 2019 to May 2023. Immunosuppression regimen, infectious complications, and graft outcomes were collected for 12 months.Results: A total of 36 patients (kidney n = 20, liver n = 9, and lung n = 7) were included in this study. Basiliximab was the most commonly employed induction strategy across the organ groups (12/20 in kidney, 4/9 in liver, and 7/7 in lung). All patients were on triple immunosuppression at 12 months posttransplant with prednisone wean achieved in one heart–liver recipient. Infection complications were frequently reported (95% kidney, 75% liver, 100% lung group). One patient went back to dialysis due to focal segmental glomerulosclerosis. One chronic lung allograft dysfunction was reported, but no other severe biopsy‐proven rejection or retransplant was reported. The 1‐year survival was 85% (17/20) in heart–kidney, 78% (7/9) in heart–liver, and 86% (6/7) in heart–lung recipients.Conclusion: This study summarized real‐world immunosuppression strategies and outcomes in dual organ heart transplant recipients.
- 8 August 2024
- Published by Wiley in Clinical Transplantation
- Vol. 38 (8) , e15420
Contemporary Immunosuppression Management and 1‐Year Outcomes in Dual Organ Heart Transplantation
Background: There have been limited reports on immunosuppression strategies and outcomes in dual organ heart transplant populations, primarily from before the 2018 United Network for Organ Sharing (UNOS) heart allocation policy change. Recent data suggested that outcomes with heart–lung and heart–liver transplants remained comparable in the new allocation era, yet heart–kidney recipients have worse 1‐year survival.Methods: This single‐center retrospective study evaluated adult heart–kidney, heart–liver, and heart–lung transplant recipients from September 2019 to May 2023. Immunosuppression regimen, infectious complications, and graft outcomes were collected for 12 months.Results: A total of 36 patients (kidney n = 20, liver n = 9, and lung n = 7) were included in this study. Basiliximab was the most commonly employed induction strategy across the organ groups (12/20 in kidney, 4/9 in liver, and 7/7 in lung). All patients were on triple immunosuppression at 12 months posttransplant with prednisone wean achieved in one heart–liver recipient. Infection complications were frequently reported (95% kidney, 75% liver, 100% lung group). One patient went back to dialysis due to focal segmental glomerulosclerosis. One chronic lung allograft dysfunction was reported, but no other severe biopsy‐proven rejection or retransplant was reported. The 1‐year survival was 85% (17/20) in heart–kidney, 78% (7/9) in heart–liver, and 86% (6/7) in heart–lung recipients.Conclusion: This study summarized real‐world immunosuppression strategies and outcomes in dual organ heart transplant recipients.
- 19 March 2024
- Published by Wiley in Clinical Transplantation
- Vol. 38 (3) , e15278
Managing the significant drug‐drug interaction between isavuconazole and tacrolimus in solid organ transplant recipients
- 19 March 2024
- Published by Wiley in Clinical Transplantation
- Vol. 38 (3) , e15278
Managing the significant drug‐drug interaction between isavuconazole and tacrolimus in solid organ transplant recipients
- Open Access
- 21 February 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (6) , 1027-1034
Obesity is associated with a higher incidence of rejection in patients on belatacept: A pooled analysis from the BENEFIT/BENEFIT-EXT clinical trials
- 21 February 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (6) , 1027-1034
Open AccessObesity is associated with a higher incidence of rejection in patients on belatacept: A pooled analysis from the BENEFIT/BENEFIT-EXT clinical trials
- 15 February 2023
- Published by Wiley in Clinical Transplantation
- Vol. 37 (4) , e14929
Real world experience with Maribavir for the treatment of cytomegalovirus in solid organ transplant recipients
- 15 February 2023
- Published by Wiley in Clinical Transplantation
- Vol. 37 (4) , e14929
Real world experience with Maribavir for the treatment of cytomegalovirus in solid organ transplant recipients
- Open Access
- 30 December 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (11) , 2682-2688
COVID-19 therapeutics and outcomes among solid organ transplant recipients during the Omicron BA.1 era
- 30 December 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (11) , 2682-2688
Open AccessCOVID-19 therapeutics and outcomes among solid organ transplant recipients during the Omicron BA.1 era
- 1 June 2022
- Published by Wiley in Transplant Infectious Disease
- Vol. 24 (4) , e13869
Maribavir does not significantly influence tacrolimus dose requirements in solid organ transplant recipients
- 1 June 2022
- Published by Wiley in Transplant Infectious Disease
- Vol. 24 (4) , e13869
Maribavir does not significantly influence tacrolimus dose requirements in solid organ transplant recipients
- Top Cited PapersOpen Access
- 21 March 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (8) , 2083-2088
Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients
- 21 March 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (8) , 2083-2088
Top Cited PapersOpen AccessEarly clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients
- 15 January 2022
- Published by Wiley in Clinical Transplantation
- Vol. 36 (3) , e14594
Nitazoxanide treatment for norovirus infection in solid organ transplant recipients
- 15 January 2022
- Published by Wiley in Clinical Transplantation
- Vol. 36 (3) , e14594
Nitazoxanide treatment for norovirus infection in solid organ transplant recipients
- Open Access
- 11 January 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (7) , 1925-1926
Nirmatrelvir/ritonavir use: Managing clinically significant drug-drug interactions with transplant immunosuppressants
- 11 January 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (7) , 1925-1926
Open AccessNirmatrelvir/ritonavir use: Managing clinically significant drug-drug interactions with transplant immunosuppressants
- 10 November 2021
- Published by Wiley in Clinical Transplantation
- Vol. 36 (2) , e14529
Comparing weight‐based dosing of tacrolimus XR in obese and non‐obese renal transplant recipients
The recommended initial weight‐based dose of extended‐release (XR) tacrolimus (Envarsus XR) in kidney transplant recipients (KTR) is 0.14 mg/kg/day. However, no data exist regarding dosing recommendations for obese patients specifically. The aim of this study was to evaluate weight‐based dosing requirements in a cohort of obese KTR who were initiated on de novo tacrolimus XR post‐transplantation. The primary outcome was weight‐based dosing requirements (mg/kg/day) on post‐operative day (POD) 7 and 14. Of the 254 KTR, 81 (31%) were obese. The median therapeutic dose on POD7 was 0.1 versus 0.12 vs. 0.14 mg/kg/day in the BMI > 30 kg/m2, BMI 25–30 kg/m2, and BMI < 25 kg/m2, respectively, (p = .0001). This result was similar on POD14; median therapeutic dose was 0.09 versus 0.11 versus 0.15 mg/kg/day in the BMI > 30 kg/m2, BMI 25–30 kg/m2, and BMI < 25 kg/m2, respectively, (p < .001). Therapeutic dose on POD7 and POD14 based on ideal body was similar in all cohorts (p = .238, p = .923, respectively). This finding was supported by a strong linear relationship between ideal body weight (IBW) and therapeutic dose (r = .929). In both obese and non‐obese KTR, IBW had a stronger correlation with the therapeutic dose for tacrolimus XR.
- 10 November 2021
- Published by Wiley in Clinical Transplantation
- Vol. 36 (2) , e14529
Comparing weight‐based dosing of tacrolimus XR in obese and non‐obese renal transplant recipients
The recommended initial weight‐based dose of extended‐release (XR) tacrolimus (Envarsus XR) in kidney transplant recipients (KTR) is 0.14 mg/kg/day. However, no data exist regarding dosing recommendations for obese patients specifically. The aim of this study was to evaluate weight‐based dosing requirements in a cohort of obese KTR who were initiated on de novo tacrolimus XR post‐transplantation. The primary outcome was weight‐based dosing requirements (mg/kg/day) on post‐operative day (POD) 7 and 14. Of the 254 KTR, 81 (31%) were obese. The median therapeutic dose on POD7 was 0.1 versus 0.12 vs. 0.14 mg/kg/day in the BMI > 30 kg/m2, BMI 25–30 kg/m2, and BMI < 25 kg/m2, respectively, (p = .0001). This result was similar on POD14; median therapeutic dose was 0.09 versus 0.11 versus 0.15 mg/kg/day in the BMI > 30 kg/m2, BMI 25–30 kg/m2, and BMI < 25 kg/m2, respectively, (p < .001). Therapeutic dose on POD7 and POD14 based on ideal body was similar in all cohorts (p = .238, p = .923, respectively). This finding was supported by a strong linear relationship between ideal body weight (IBW) and therapeutic dose (r = .929). In both obese and non‐obese KTR, IBW had a stronger correlation with the therapeutic dose for tacrolimus XR.